<ul><li>RenovoRx, Inc. is increasing production of its FDA-cleared RenovoCath catheter-based device to meet the growing demand for targeted drug delivery in oncology.</li><li>The initial total addressable market for RenovoCath is estimated to be approximately $400 million in peak annual U.S. sales.</li><li>RenovoRx's first-quarter 2025 revenue from RenovoCath is expected to reach the low six-figure range, with continued quarterly growth throughout the year.</li><li>Members of RenovoRx's management team and Board of Directors have shown confidence in the company's business plan by purchasing an aggregate of 143,145 shares of RenovoRx stock.</li></ul>

Renovo Gains on Bringing Forward RenovoCath

Discover more